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Abstract
Background: Postreperfusion syndrome and haemodynamic instability are predictors for poor outcome after liver
transplantation. Cytokine release has been claimed to be responsible for postreperfusion syndrome. However, the
underlying pathophysiologic mechanism is not clarified.
The aim of this prospective observational study was to correlate cardiac performance (measured by
transoesophageal echocardiography (TEE), Doppler and Tissue Doppler Imaging (TDI)) to plasmatic cytokines: IL-6,
IL-8, CXCL1, TGF-β and CD40L at 5 different time points during liver transplantation.
Methods: Seventeen consecutive patients scheduled for orthotopic liver transplantation, age 18 to 75 years
without contraindication for transoesophageal echocardiography were included. Patients were monitored with TEE
and TDI.
Systolic and diastolic cardiac function, MAP, MPAP, CVP, PCWP, CO and blood samples for cytokine assays were
recorded or collected after induction, 15 min after vena cava inferior clamping, 2 to 5 min after reperfusion, 60 min
after reperfusion and at the end of surgery.
Results: Mean arterial pressure and catecholamine requirements remained unchanged, MPAP, CVP and CO
increased, SVR decreased after unclamping. Postreperfusion syndrome did not develop. The haemodynamic
parameters and the variations of TEE parameters were consistent with the volume load changes during clamping
and declamping and did not reveal systolic or diastolic cardiac dysfunction. All cytokines, except TGF-β, increased.
Conclusion: These findings suggest, that significant cytokine release during liver transplantation is not necessarily
coincident with haemodynamic instability and impaired cardiac function.
Trial registration: ClinicalTrials.gov: NCT00547924
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Background
Reperfusion of the liver graft is one of the most critical
periods during liver transplantation. Several factors may
contribute to immediate haemodynamic instability after
reperfusion, so called the postreperfusion syndrome
(PRS). Free radicals, proinflammatory cytokines, meta-
bolic acidosis, electrolyte disturbances and elevation of
cyclic guanosine monophosphate (cGMP) have been re-
ferred to as possible causative factors [1–3]. Haemo-
dynamic instability in the context of PRS is defined as a
decrease of mean arterial blood pressure of more than
30 % in the first 5 min after graft reperfusion continuing
for at least 1 min [4, 5]. Its incidence is reported to be 8-
50 % and it is associated with substantial increase in peri-
operative complications and lower early survival [6–8].
Several studies identified cardiac failure as primary cause
for PRS [9, 10]. However, both the responsible pathophysi-
ologic mechanism for haemodynamic instability after re-
perfusion and the significant correlation between cytokine
release and impaired cardiac function have not been dem-
onstrated yet.
The purpose of this study was to measure proinflamma-
tory cytokines and systolic and diastolic cardiac function
with TEE using 2D, Doppler and Tissue Doppler Imaging
(TDI) at different stages before and after hepatic reperfu-
sion. Doppler echocardiography in association with TDI is
a very sensitive method for the evaluation of diastolic
function [11] and has not been applied in liver transplant-
ation so far. We hypothesized, that an increase of washed
in proinflammatory mediators from the liver graft might
impair ventricular function after reperfusion.
Methods
Ethics
This prospective, observational study was approved by
the local Ethics Committee (Kantonale Ethikkommission
Zürich, approved on 4th May 2006) Ref.Nr. StV 11-2006,
ClinicalTrials.gov Identifier: NCT00547924.
Patients
Twenty consecutive patients on the Swiss Transplant liver
transplantation waiting list were enrolled between 03/2007
and 02/2010. Written consent of all patients was obtained
prior to transplantation. Patients between 18 to 75 years
were included. Exclusion criteria were participation in a dif-
ferent study, contraindications for transoesophageal echo-
cardiography: constrictions, tumours, varicose veins or a
diverticulum in the oesophagus and cervical instability.
Measurement time points
Mean arterial pressure (MAP), mean pulmonary arterial
pressure (MPAP), central venous pressure (CVP), pul-
monary capillary wedge pressure (PCWP), cardiac output
(CO), systemic vascular resistance (SVR) and all blood
samples for cytokine assays and arterial blood gas analysis
were recorded or collected at the following time points:
baseline, after induction of anaesthesia (A), 15 min after
vena cava inferior clamping (prior to reperfusion) (B), 2 to
5 min after reperfusion and declamping of vena cava infer-
ior (C), 60 min after reperfusion (D), at the end of surgery
(E). TEE measurements were performed at time points A,
B, C and D.
Anaesthesia and monitoring
Anaesthesia and monitoring were performed following an
institutional protocol. Anaesthesia was induced with propo-
fol, fentanyl and rocuronium or atracurium and maintained
with sevoflurane or isoflurane, fentanyl and atracurium. A
central venous line, a pulmonary artery catheter, a femoral
arterial and one or more peripheral venous lines were in-
stalled. TEE was performed, unless there was a recent
bleeding from oesophageal varicose veins or hypocoagul-
ability with prothrombin time (Quick value) less than 20 %
(institutional laboratory reference) or platelet count less
than 30000/ml. Other indications and contraindications re-
ferred to the practice guidelines for perioperative TEE of
the American Society of Anesthesiologists [12, 13]. All
echocardiographic studies were performed by the same ex-
perienced cardiac anaesthetist (Dominique Bettex), who is
an expert in TEE.
TEE measurements and technique
Data acquisition was performed by a multiplane transoe-
sophageal echocardiography probe and an echocardiog-
raphy apparatus GE Vivid 7 or Vivid Q (System V7 or
VQ, GE Vingmed, Horten, Norway, 5.5 MHz trans-
ducer). Measurements with TEE were collected at the
four time points A, B, C, and D to assess systolic and
diastolic function of the left ventricle (LV): fractional
area change (FAC) in transgastric short-axis view (end-
diastolic area – endsystolic area/enddiastolic area), ejec-
tion fraction (EF) using the modified Simpson’s rule [14]
in mid-oesophageal four- and two-chamber views or
Teichholz method [15] in transgastric short-axis view
were recorded for the assessment of LV systolic function.
Different measurements of systolic function were used,
because the transgastric views were not always available,
particularly during liver grafting. In case of a discrepancy
of the various measurements we relied on EF measured
according to Simpson’s rules. Color M-mode Doppler
was performed in mid-oesophageal four-chamber view
in the standard manner defined previously to obtain the
flow propagation velocity (Vp), indicative of the LV re-
laxation [16]. The transmitral Doppler flow was obtained
with the Doppler interrogation window placed at the
leaflet tips of the mitral valve and the maximum trans-
mitral velocities of the early filling or E wave and late
filling or A wave, the ratio E/A, and deceleration time
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(DT) of the E wave were measured. The isovolumetric re-
laxation time (IVRT) was obtained after a slight modifica-
tion of the interrogation window into the left ventricular
outflow tract. Finally, tissue pulse-Doppler imaging was
obtained during apnoea on the mid-oesophageal four-
chamber view, placing the region of interest at the level of
the mitral annulus on the lateral as well as on the med-
ial aspects; the maximum velocities of systolic wave
(S’), and diastolic waves (E’ and A’) were collected and
the ratios E’/A’ and E/E’ were calculated. The diastolic
function was assessed as described previously [11, 17].
The ratio E/E’ was used as criteria for high LV filling
pressure as follow: E/E’ > 15, LAP > 18mmHg; E/E’ < 8,
LAP = 10-12mmHg [18, 19].
Enzyme-linked immunosorbent assay (ELISA)
Concentrations of various cytokines in plasma were deter-
mined as previously described [20]: interleukin-6 (IL-6),
interleukin-8 (IL-8), chemokine (C-X-C motif) ligand 1
(CXCL1), transforming growth factor-β (TGF-β), CD40 lig-
and (CD40L) and tumour necrosis factor alpha (TNF-α).
Sandwich ELISAs were performed according to the manu-
facturer’s protocol (R&D Systems Europe Ltd, Abingdon,
UK). Detection limits of the ELISA were determined by
the manufacturer (R&D Systems Europe Ltd) as follows:
for IL-6 9.37 pg/ml, for IL-8, TGF-β and CXCL1 31.25 pg/
ml and for CD40L 15.65 pg/ml.
Statistics
Continuous variables are presented as mean with stand-
ard deviation (SD) and are compared between different
time points using the paired t-test. Variables were loga-
rithmised for these analyses if appropriate. P-values less
than 0.05 are considered significant. The Bonferroni-
correction was used to address the problem of multiple
comparisons. As there are 5 comparisons between time
points A/B, A/C, B/C, C/D, and D/E for each variable,
p-values less than 0.01 are considered significant in these
analyses. IBM SPSS Statistics 20 (SPSS Inc., Chicago, IL)
was used for statistical analyses.
Results
After enrolment 3 patients had to be excluded for differ-
ent reasons: pancreatic carcinoma of the donor, diagnosed
in situ (n = 1), unavailability of the TEE specialist (n = 1)
and blood samples for cytokine assays were not cooled
and centrifuged after sampling (n = 1). Patient characteris-
tics and surgical data of the remaining 17 patients are
shown in Table 1.
Surgical procedures
Standard technique with cross clamping of the vena cava
inferior was used in 11 patients, partial clamping of the
vena cava inferior (piggyback technique) in 6 cases. One
re-transplantation and 3 living donor transplantations
were performed. Veno-venous bypass was not used.
Blood flush of 200-400 ml was drained from the liver
graft prior to reperfusion according to the institutional
protocol. In all cases surgery was performed by one of
two experienced liver surgeons.
Donor and graft criteria
Detailed information about donor age, the cause of
death or the reason for donation and cold ischemia time
can be found in Table 2.
Haemodynamic parameters
Haemodynamic parameters were compared regarding
changes from baseline to clamping (A to B), baseline to
immediate reperfusion (A to C), clamping to immediate
reperfusion (B to C), immediate reperfusion to 1 h after
reperfusion and 1 h after reperfusion to end of surgery.
Results are shown in Tables 3, 4 and Fig. 1. Significant
changes in haemodynamic parameters were documented
from cross clamping to immediate reperfusion for all pa-
rameters except for stable MAP: MPAP, CVP and CO
increased, whereas SVR decreased. Haemodynamic cri-
teria for PRS were not fulfilled.
Table 1 Patient characteristics and surgical data
Age, years (n = 17) 591 (42-68)
Female, n 5
Male, n 12
Duration of Surgery 4402 (100)
MELD score 15.72 (9.9)
Alcoholic Cirrhosis, n 3
Cryptogenic Cirrhosis, n 3
Hepatitis C Cirrhosis, n 3
Hepatitis B Cirrhosis, n 2
Hepatitis C and Hepatocellular Carcinoma, n 2
Hemochromatosis, Hepatocellular Carcinoma, n 1
Hepatocellular Carcinoma, n 1
Graft Rejection, n 1
Primary Biliary Cirrhosis. n 1
LV EF <50 %, n 0
Coronary Heart Disease, n 1
0-1 cardiovascular risk-factor3, n 10
≥2 cardiovascular risk-factors3, n 7
1Median (range)
2Mean (standard deviation)
3Modifiable cardiovascular risk factors according to WHO: Hypertension,
smoking, diabetes and overweight and obesity; physical inactivity was
excluded (Mendis S, Puska P, Norrving B: Global Atlas on Cardiovascular
Disease Prevention and Control, 2011, ISBN-13 9789241564373)
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Vasopressors
The continuous noradrenaline administration after clamp-
ing was 9.4 ± 8.6 μg/min and hence similar to the continu-
ously administered dose after reperfusion 11.0 ± 7.0 μg/min
(B to C). In only 6 out of 17 patients a small bolus of nor-
adrenaline, adrenaline or neosynephrine was required.
TEE parameters
Transoesophageal echocardiography was uneventful in all
patients, there was no oesophageal bleeding after insertion
of the echo probe. Several measurements of systolic and
diastolic function were performed simultaneously to the
collection of the haemodynamic parameters. The results
are shown in Tables 4 and 5. Statistically significant varia-
tions of the transmitral flow (E,A, E/A), flow propagation
velocity (FPvel) and early and late peak diastolic velocity
(E’, A’, E’/A’) of the mitral annulus were documented,
mostly between baseline (A) and after clamping of the
vena cava (B), as well as immediately after reperfusion of
the liver (C). These variations were compatible with acute
intravascular volume variations and did not demonstrate
any systolic or diastolic dysfunction at any time during
transplantation. There were no statistically significant
changes between baseline (A) and post reperfusion steady
state (D).
Cytokines
Absolute values are indicated in Table 6, significant
changes of values in Table 4. Comparing time points A
to D an increase of IL-6, IL-8 was observed, comparing
A to C: IL-6, IL-8 and CXCL1 increased. No significant
changes were observed for TGF-β and CD40L (Tables 4
and 6). For IL-6 an increased concentration was found at
time points B and C compared to A (for both p < 0.001).
At time point C IL-6 value was higher than at time point
B (p = 0.007). Interleukin-8 concentrations were higher at
time point B as well as C in comparison to A (p = 0.01
and p = 0.001, respectively). At time point D concentra-
tion significantly exceeded the value from time point C
(p = 0.003). A significant change was measured for
CXCL1 at time point C compared to A (p < 0.001) as
well as to B (p = 0.006). Concentrations of TGF-β and
CD40L did not differ over time. TNF-α was below de-
tection range.
Discussion
In contrast to our hypothesis, we found no postreperfu-
sion syndrome and cardiac performance was not impaired
in terms of systolic or diastolic function despite increased
cytokine levels throughout the course of liver transplant-
ation. Moreover, haemodynamic and echocardiographic
parameters reflected the physiological haemodynamic
changes due to clamping and unclamping of the vena cava
and the consecutive measures like volume loading or ad-
ministration of catecholamines.
Haemodynamic instability after reperfusion of the liver
graft is a major concern in liver transplantation and corre-
lated to poor outcome [6]. In the last two decades many
causal factors have been investigated, but none of them has
proven the primarily responsible. Even the amount of cate-
cholamines used for liver transplantation was analysed, but
no significant correlation with cytokine release was found
[21]. The aim of the present study was to evaluate cardiac
performance during liver transplantation and the reperfu-
sion period via TEE and to assess the simultaneous cyto-
kine release. We found decreased filling pressures, cardiac
output and a compensatory increase of SVR after clamp-
ing. The reverse was documented after unclamping. The
significant decrease of SVR after unclamping and reperfu-
sion may be interpreted as a cytokine induced effect, also
seen after cardiopulmonary bypass [22]. MAP was main-
tained and CO increased in terms of a compensatory
Table 2 Donor and Graft Criteria
Age in years 57.4 (19.5)
Diagnosis Intracranial haemorrhage 10
Living donation 3
Cerebral oedema due to meningeoma 1
Trauma 1
Anoxia after myocardial infarction 1
Asphyxia 1
Cold ischemia
time (minutes)
440 (216)
Table 3 Haemodynamic parameters
A B C D E
Baseline Clamping Imm. Reperfusi on1 1h Reperfusion End of surgery
MAP (mmHg) 73 (9) 71 (9) 66 (12) 66 (5) 67 (7)
MPAP (mmHg) 22 (6) 17 (7) 25 (7) 23 (8) 23 (7)
PCWP (mmHg) 15 (5) 12 (6) 18 (7) 14 (6) 16 (6)
CVP (mmHg) 13 (4) 9 (6) 14 (5) 12 (6) 12 (5)
CO (L/min) 5.8 (1.9) 4.4 (1.8) 8.5 (2.8) 8.1 (2.9) 8.1 (2.9)
SVR (dyn · s · cm−5) 900 (325) 1298 (768) 680 (642) 672 (430) 652 (464)
1Immediate reperfusion
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hyperdynamic state. Transoesophageal echocardiographic
parameters proceeded similarly. There was no sign of sys-
tolic or diastolic dysfunction at any time during the trans-
plantation. However, we are aware of the fact that FAC or
EF rather reflect the adaptation to the loading conditions
of the heart than inotropy. However, s’, being is less load
dependent than FAC or EF, was relatively stable over the
course of the transplantation and confirmed our conclu-
sion. Unfortunately, we did not keep track of the acceler-
ation time of s’, which might have been a less load
dependent echocardiographic assessment of systolic func-
tion. The variations in transmitral flow, flow propagation
velocity and early and late peak diastolic velocity of the mi-
tral annulus were all compatible with the relevant volume
variations during the clamping of the vena cava and imme-
diately after the reperfusion of the liver. They varied ac-
cording to the haemodynamic parameters and recovered at
the end of the procedure.
Two cytokines are considered major cardiac depres-
sants: IL-6 [23] and TNF-α [24] and therefore especially
interesting to answer the question raised in this study.
TNF-α was below the detection level in all of our patients.
In comparison to former liver transplantation trials we
also have assessed markers that act on the various different
inflammatory cells (neutrophils, macrophages, T-cells) and
expanded our search pattern of inflammatory mediators to
determine also molecules, not having been evaluated be-
fore. Although not significant for all parameters, there was
an increase in cytokine levels during liver transplantation.
Most recently, Bezinover and collegues suggested an
association between plasma cyclic guanosine monopho-
sphate levels and haemodynamic instability during liver
transplantation [3]. Similar to their previous study [21]
they compared again the amount of catecholamines used
to the levels of cGMP. However, choosing the amount of
catecholamines as an indicator of haemodynamic stabil-
ity may be misleading. Many other factors may contrib-
ute to catecholamine use during liver transplantation:
patients often have a more or less pronounced hyperdy-
namic circulation with splanchnic vasodilation and a
collateral circulation [25] advanced cirrhosis may lead to
cardiomyopathy [26]. In addition the recipient may suf-
fer from cardiovascular comorbidities. The preoperative
coagulation profile may influence the amount and pace
Table 4 Changes of cytokines, echocardiographic and haemodynamic parameters
Cytokines4 Echocardiographic Parameters Haemodynamic Parameters
IL 6 A/B ↑ p < 0,001 DT n.s. MAP n.s.
B/C ↑ p = 0,007 IVRT n.s.
A/C ↑ p < 0,001 FP vel A/C ↑ p = 0,009 MPAP B/C ↓ p < 0,001
IL 8 A/B ↑ p = 0,01 B/C ↑ p = 0,001
A/C ↑ p = 0,001 E lat A/B ↓ p < 0,001 CVP B/C ↑ p = 0,001
C/D ↑ p = 0,003 B/C ↑ p < 0,001
CXCL1 A/C ↑ p < 0,001 A lat A/C ↑ p = 0,001 PCWP B/C ↑ p < 0,001
B/C ↑ p = 0,006 E/A lat A/B ↓ p = 0,003
TGF-β n.s. S’ lat n.s. B/C ↑ p < 0,001
CD40L n.s., ↑ trend for A/C S’ sept n.s.
E sept A/B ↓ p = 0,002 SVR4 A/B ↑ p = 0,004
B/C ↑ p < 0,001 A/C ↓ p = 0,002
A sept A/C ↑ p = 0,007 B/C ↓ p < 0,001
E/A sept A/B ↓ p = 0,004
E/E sept n.s.
EDA n.s.
ESA C/D ↑ p = 0,005
EF n.s.
Peak E A/B ↓ p < 0,001
B/C ↑ p < 0,001
Peak A B/C ↑ p = 0,002
E/A A/B ↓ p < 0,001
B/C ↑ p = 0,001
4Values are logarithmized
n.s. = not significant
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Fig. 1 Haemodynamic parameters. Mean arterial pressure (a), cardiac output (b) and systemic vascular resistance (c) at the different time points
of the study. ¶ increase of cardiac output from a baseline to c immediate reperfusion (p < 0,001). § increase of cardiac output from b clamping
the vena cava inferior to c immediate reperfusion (p < 0,001). + increase of systemic vascular resistance from a baseline to b clamping the vena
cava inferior (p = 0,004). # decrease of systemic vascular resistance from a baseline to c immediate reperfusion (p = 0,002). ‡ decrease of systemic
vascular resistance from b clamping the vena cava inferior to c immediate reperfusion (p < 0,001)
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of blood loss, which might also impact on the haemo-
dynamic situation, and catecholamine use of the recipient.
Also the skills and experience of the surgeon, which have
a proven impact on outcome in advanced bariatric surgery
[27], the hospital’s standard operating procedures for
haemodynamic management and the individual experi-
ence and skills of the anaesthetist, might all impact on the
use of catecholamines in liver transplant patients. The re-
sults of this study have to be interpreted in the back-
ground of the low caseload and all factors mentioned
above. Furthermore, the considerably varying occurrence
of PRS in the literature underlines this statement. The
incidence reported ranges from 8 % to 50 % [6, 8]. How-
ever, at our institution we have a detailed protocol for the
anaesthetic management of liver transplantation and a
specially trained team of consultants for liver and lung
transplantation. In addition, one or the other of only two
surgical team leaders was involved in all cases. This may
have counteracted to individual differences and possibly
strengthened the relevance of our results.
As mentioned above, there was no PRS and no impaired
cardiac function during the whole procedure, while the
level of most proinflammartory cytokines increased sig-
nificantly (with exception of TNF-α, TGF-β and CD40L).
The increase was similar to earlier studies, where either
coincidental haemodynamic impairment was found [28]
or not present [21]. Increased cytokines without impact
on cardiac function are also regularly seen after cardiopul-
monary bypass in cardiac surgery [22].
A possible explanation for not observing PRS in our
study population might be a rather low MELD-score, a
good preoperative cardiac function as well as the good
quality of donor organs. Cardiac output seems to adapt
pretty well in response to stress in patients with a low
MELD score, but even at this early stage of the disease,
heart mass and the enddiastolic volume increase with
higher scores [29]. As the disease progresses, the changes
in structure and function aggravate [30]. In most patients,
diastolic dysfunction seems to progress along with the
progress of the disease [31], whereas systolic dysfunction
only develops in a subset of patients [32].
Study limitations might be, that our patients had a rather
low MELD score and a good cardiac baseline function.
This makes the study population more homogenous on
one hand but is likely not to reflect the full spectrum of
changes related to end stage liver disease, especially in pa-
tients with a high MELD score. Also the low patient num-
ber may be considered a limitation of the current study.
Strength of the study is the quality of the data and detailed
echocardiography data. Since only our most experienced
echocardiologist performed all echoes and measurements,
we can assume that the quality of the measurements is very
high and an inter-investigator variation can be excluded.
The quality of the grafts was considered very good and
although we observed a significant increase of some cyto-
kines. We cannot exclude that a more pronounced cyto-
kine release could have impacted on cardiac function.
We hope that our study lays ground for a larger study,
observing patients in a more advanced stage of end stage
liver disease, as PRS may be more frequent in this patient
population and may thus uncover whether the pathophysi-
ology of PRS is related to cardiac function or to vasoplegia.
Conclusion
In conclusion, echocardiographic and haemodynamic find-
ings did not show neither impaired systolic and diastolic
Table 5 Echocardiographic Parameters
A B C D
Baseline Clamping Imm.
Reperfusion1
1h
Reperfusion
DT (msec) 236 (49.3) 227 (43.8) 225 (41.8) 223 (47.7)
IVRT (msec) 89 (29.1) 102 (36.5) 90.5 (34.7) 99.2 (34.9)
FP vel (cm/sec) 54 (16.3) 45 (15.1) 63 (16.3) 63 (15.8)
E’ lat (cm/sec) 12 (3.5) 9.2 (2.4) 12.4 (2.8) 12.3 (2.6)
A’ lat (cm/sec) 11.3 (3.4) 11.7 (4.1) 14.1 (3.8) 13.4 (3.6)
E’/A’ lat 1.15 (0.5) 0.9 (0.4) 0.9 (0.3) 0.95 (0.3)
E/E’ lat 5.9 (2) 5.2 (1.8) 6.5 (2.7) 7 (2.8)
S’ lat (cm/sec) 9.6 (2) 11.2 (3.5) 12 (4.1) 11.9 (4.4)
S’ sept (cm/sec) 9 (3.1) 8.6 (4) 9.2 (1.8) 9.1 (2.1)
E’ sept (cm/sec) 8.2 (2.7) 5.8 (2.3) 9.7 (3.3) 9.2 (2.4)
A’ sept (cm/sec) 8.2 (2.9) 8.4 (3.2) 10.4 (3.2) 10.3 (2.9)
E’/A’ sept 1.1 (0.4) 0.8 (0.4) 1 (0.3) 0.95 (0.2)
E/E sept 8.9 (3.4) 8.7 (3.4) 8.2 (3.4) 9.35 (3.6)
EDA (cm2) 21.4 (6.7) 16.9 (7) 20.5 (5.5) 24 (6.5)
ESA (cm2) 10 (4.6) 7.1 (3.6) 6.8 (2.5) 8.3 (2.3)
EF2 (%) 72 (9.4) 78 (9) 79 (7.4) 78 (10.9)
Peak E (cm/sec) 67.7 (16.5) 46.1 (13.2) 75 (21.7) 80.2 (14.8)
Peak A (cm/sec) 56.8 (16.3) 48.1 (12.3) 62.4 (17.7) 67.2 (18.3)
E/A 1.27 (0.44) 0.96 (0.32) 1.21 (0.25) 1.23 (0.25)
1Immediate reperfusion
2EF obtained by Simpson’s rules
Table 6 Cytokines
A B C D E
Baseline Clamping Imm.
Reperfusion1
1h
Reperfusion
End of
surgery
IL-6 30 (103) 216 (145) 313 (203) 547 (451) 552 (499)
IL-8 26 (52) 42 (60) 49 (70) 123 (184) 132 (109)
CXCL1 89 (259) 104 (277) 173 (330) 166 (321) 145 (278)
TGF-β 93 (78) 104 (86) 83 (57) 98 (63) 100 (63)
CD40L 1344
(4711)
1174
(4033)
1493
(4798)
1290
(4468)
1284
(4462)
1Immediate reperfusion
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cardiac function nor severe haemodynamic instability
during reperfusion of the liver graft, although there was
an increase in cytokine levels during liver transplant-
ation. These findings suggest, that significant cytokine
release during liver transplantation is not necessarily
coincident with haemodynamic instability and impaired
cardiac function.
Abbreviations
A wave: Peak late (atrial contraction) transmitral flow velocity; A’lat/sept: Late
diastolic peak tissue velocity of the lateral and septal mitral annulus using
tissue pulsed wave Doppler imaging; CD40L: CD40 ligand, soluble CD40;
cGMP: Cyclic Guanosine Monophosphate; CO: Cardiac Output; CVP: Central
Venous Pressure; CXCL1: Chemokine (C-X-C motif) ligand 1; DT: Deceleration
Time of the E Wave; E/A: Ratio of the early over late transmitral flow
velocities; EDA: Enddiastolic Area; E/E’: Ratio of the early transmitral flow over
the early diastolic peak velocity of the mitral annulus; EF: Ejection Fraction;
E’lat/sept: Early diastolic peak tissue velocity of the lateral and septal mitral
annulus using tissue pulsed wave Doppler imaging; ESA: Endsystolic Area; E
wave: Peak early transmitral flow velocity; FAC: Fractional Area Change; FP
vel: color M-mode flow propagation velocity; IL-6: Interleukin-6; IL-8:
Interleukin-8; IVRT: Isovolumetric Relaxation Time; LV: Left Ventricle; MAP: Mean
Arterial Pressure; MELD: Model of End-stage Liver Disease; MPAP: Mean
Pulmonary Arterial Pressure; PCWP: Pulmonary Capillary Wedge Pressure;
PRS: Post Reperfusion Syndrome; S’lat/sept: Peak systolic velocity of the lateral
and septal mitral annulus using tissue pulsed wave Doppler imaging;
SVR: Systemic Vascular Resistance; TDI: Tissue Doppler Imaging;
TEE: Transoesophageal Echocardiography; TGF-β: Transforming Growth
Factor-beta; TNF-α: Tumour Necrosis Factor-alpha; 2D: Two-dimensional
echocardiography.
Competing interests
MPZ, MS, BBS, BS and DB declare no competing interests related to the
current study.
DRS’s academic department is receiving grant support from the Swiss
National Science Foundation, Berne, Switzerland, the Ministry of Health
(Gesundheitsdirektion) of the Canton of Zurich, Switzerland for Highly
Specialized Medicine, the Swiss Society of Anesthesiology and Reanimation
(SGAR), Berne, Switzerland, the Swiss Foundation for Anesthesia Research,
Zurich, Switzerland, Bundesprogramm Chancengleichheit, Berne, Switzerland,
CSL Behring, Berne, Switzerland, Vifor SA, Villars-sur-Glâne, Switzerland.
Dr. Spahn was the chairman of the ABC Faculty and is the co-chairman of
the ABC-Trauma Faculty, which both are managed by Physicians World
Europe GmbH, Mannheim, Germany and sponsored by unrestricted educational
grants from Novo Nordisk Health Care AG, Zurich, Switzerland, CSL Behring
GmbH, Marburg, Germany and LFB Biomédicaments, Courtaboeuf Cedex, France.
In the past 5 years, Dr. Spahn has received honoraria or travel support for
consulting or lecturing from the following companies: Abbott AG, Baar,
Switzerland, AMGEN GmbH, Munich, Germany, AstraZeneca AG, Zug, Switzerland,
Bayer (Schweiz) AG, Zürich, Switzerland, Baxter AG, Volketswil, Switzerland, Baxter
S.p.A., Roma, Italy, B. Braun Melsungen AG, Melsungen, Germany,
Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Bristol-Myers-Squibb,
Rueil-Malmaison Cedex, France and Baar, Switzerland, CSL Behring GmbH,
Hattersheim am Main, Germany and Berne, Switzerland, Curacyte AG, Munich,
Germany, Ethicon Biosurgery, Sommerville, New Jersey, USA, Fresenius SE, Bad
Homburg v.d.H., Germany, Galenica AG, Bern, Switzerland (including Vifor SA,
Villars-sur-Glâne, Switzerland),GlaxoSmithKline GmbH & Co. KG, Hamburg,
Germany, Janssen-Cilag AG, Baar, Switzerland, Janssen-Cilag EMEA, Beerse,
Belgium, Merck Sharp & Dohme AG, Luzern, Switzerland, Novo Nordisk A/S,
Bagsvärd, Denmark, Octapharma AG, Lachen, Switzerland, Organon AG,
Pfäffikon/SZ, Switzerland, Oxygen Biotherapeutics, Costa Mesa, CA, Photonics
Healthcare GmbH, Munich, Germany, ratiopharm Arzneimittel Vertriebs-GmbH,
Vienna, Austria, Roche Diagnostics International Ltd, Reinach, Switzerland, Roche
Pharma (Schweiz) AG, Reinach, Switzerland, Schering-Plough International, Inc.,
Kenilworth, New Jersey, USA, Tem International GmbH, Munich, Germany,
Verum Diagnostica GmbH, Munich, Germany, Vifor Pharma Deutschland GmbH,
Munich, Germany, Vifor Pharma Österreich GmbH, Vienna, Austria, Vifor
(International) AG, St. Gallen, Switzerland.
Authors’ contributions
MPZ and DB designed the study; MPZ, DB and BBS performed the study;
MPZ, MS, BBS, BS, DRS and DB analysed the data; MPZ wrote the manuscript;
MS, BBS, DRS and DB revised the manuscript. All authors read and approved
the final manuscript.
Acknowledgments
Funding
MPZ, MS, BBS, BS, DRS and DB: Institutional funding.
Disclaimer in relation to the above conflict-of-interest statement
None of the above listed companies and/or entities have been directly or
indirectly involved in discussing and/or developing this manuscript or parts
thereof. None of them have financially contributed to this endeavor in
whatever form, neither directly nor indirectly. Therefore it is beyond my
capacity to tell whether any of the above listed companies and/or entities
do or do not have a direct financial interest in the subject matter or
materials discussed in this manuscript.
Author details
1Institute of Anaesthesiology, University and University Hospital Zürich,
Raemistrasse 100, 8091 Zürich, Switzerland. 2Institute of Physiology, University
Zurich Irchel, 8057 Zurich, Switzerland. 3Department of Anesthesiologoy,
University of Illinois at Chicago, 60612 Chicago, USA. 4Department of
Biostatistics, Epidemiology, Biostatistics and Prevention Institute, University of
Zurich, 8001 Zurich, Switzerland. 5Institute of Anaesthesiology, University
Children’s Hospital Zurich, 8032 Zurich, Switzerland.
Received: 13 April 2015 Accepted: 24 June 2015
References
1. Aggarwal S, Kang Y, Freeman JA, Fortunato Jr FL, Pinsky MR. Postreperfusion
syndrome: hypotension after reperfusion of the transplanted liver. J Crit
Care. 1993;8(3):154–60.
2. Fukuzawa K PE. The Post-Reperfusion Syndrome: Diagnosis, Incidence and
Management. In: Liver Transplantation - Basic Issues. edn. Edited by H A.
Winchester GB: Intech Open Science; 2012:385–96.
3. Bezinover D, Kadry Z, Uemura T, Sharghi M, Mastro AM, Sosnoski DM, et al.
Association between plasma cyclic guanosine monophosphate levels and
hemodynamic instability during liver transplantation. Liver Transpl.
2013;19(2):191–8.
4. Nanashima A, Pillay P, Crawford M, Nakasuji M, Verran DJ, Painter D. Analysis
of postrevascularization syndrome after orthotopic liver transplantation: the
experience of an Australian liver transplantation center. J Hepatobiliary
Pancreat Surg. 2001;8(6):557–63.
5. Hilmi I, Horton CN, Planinsic RM, Sakai T, Nicolau-Raducu R, Damian D, et al.
The impact of postreperfusion syndrome on short-term patient and liver
allograft outcome in patients undergoing orthotopic liver transplantation.
Liver Transpl. 2008;14(4):504–8.
6. Paugam-Burtz C, Kavafyan J, Merckx P, Dahmani S, Sommacale D, Ramsay
M, et al. Postreperfusion syndrome during liver transplantation for cirrhosis:
outcome and predictors. Liver Transpl. 2009;15(5):522–9.
7. Xu ZD, Xu HT, Yuan HB, Zhang H, Ji RH, Zou Z, et al. Postreperfusion
syndrome during orthotopic liver transplantation: a single-center experience.
Hepatobiliary Pancreat Dis Int. 2012;11(1):34–9.
8. Ayanoglu HO, Ulukaya S, Tokat Y. Causes of postreperfusion syndrome in
living or cadaveric donor liver transplantations. Transplant Proc.
2003;35(4):1442–4.
9. Ellis JE, Lichtor JL, Feinstein SB, Chung MR, Polk SL, Broelsch C, et al. Right heart
dysfunction, pulmonary embolism, and paradoxical embolization during liver
transplantation. A transesophageal two-dimensional echocardiographic study.
Anesth Analg. 1989;68(6):777–82.
10. Lichtor JL. Ventricular dysfunction does occur during liver transplantation.
Transplant Proc. 1991;23(3):1924–6.
11. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications
for the study of diastolic function. J Am Coll Cardiol. 1998;32(4):865–75.
12. Thys DM, Brooker RF, Cahalan MK, Connis RT, Duke PG, Nickinovich DG, et al.
Practice guidelines for perioperative transesophageal echocardiography. An
updated report by the American Society of Anesthesiologists and the Society
Zalunardo et al. BMC Anesthesiology  (2015) 15:107 Page 8 of 9
of Cardiovascular Anesthesiologists Task Force on Transesophageal
Echocardiography. Anesthesiology. 2010; 112(5):1084–1096.
13. Stehling LC, Dohterty DC, Faust RJ, Greenburg AG, Harrision CR, Launders
DF, et al. Practice Guidelines for blood component therapy: A report by the
American Society of Anesthesiologists Task Force on Blood Component
Therapy. Anesthesiology. 1996;84(3):732–747.
14. Chapman CB, Baker O, Reynolds J, Bonte FJ. Use of biplane cinefluorography
for measurement of ventricular volume. Circulation. 1958;18(6):1105–17.
15. Teichholz LE, Cohen MV, Sonnenblick EH, Gorlin R. Study of left ventricular
geometry and function by B-scan ultrasonography in patients with and
without asynergy. N Engl J Med. 1974;291(23):1220–6.
16. Brun P, Tribouilloy C, Duval AM, Iserin L, Meguira A, Pelle G, et al. Left
ventricular flow propagation during early filling is related to wall relaxation:
a color M-mode Doppler analysis. J Am Coll Cardiol. 1992;20(2):420–32.
17. Oh JK, Hatle L, Tajik AJ, Little WC. Diastolic heart failure can be diagnosed
by comprehensive two-dimensional and Doppler echocardiography. J Am
Coll Cardiol. 2006;47(3):500–6.
18. Arques S, Roux E, Luccioni R. Current clinical applications of spectral tissue
Doppler echocardiography (E/E’ ratio) as a noninvasive surrogate for left
ventricular diastolic pressures in the diagnosis of heart failure with
preserved left ventricular systolic function. Cardiovasc Ultrasound. 2007;5:16.
19. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, et al.
Clinical utility of Doppler echocardiography and tissue Doppler imaging in the
estimation of left ventricular filling pressures: A comparative simultaneous
Doppler-catheterization study. Circulation. 2000;102(15):1788–94.
20. De Conno E, Steurer MP, Wittlinger M, Zalunardo MP, Weder W, Schneiter D,
et al. Anesthetic-induced improvement of the inflammatory response to
one-lung ventilation. Anesthesiology. 2009;110(6):1316–26.
21. Bezinover D, Kadry Z, McCullough P, McQuillan PM, Uemura T, Welker K, et
al. Release of cytokines and hemodynamic instability during the reperfusion
of a liver graft. Liver Transpl. 2011;17(3):324–30.
22. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to
cardiac surgery: implications for the anesthesiologist. Anesthesiology.
2002;97(1):215–52.
23. Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE,
et al. Role of interleukin 6 in myocardial dysfunction of meningococcal
septic shock. Lancet. 2004;363(9404):203–9.
24. Caorsi C, Quintana E, Valdes S, Munoz C. Continuous cardiac output and
hemodynamic monitoring: high temporal correlation between plasma TNF-alpha
and hemodynamic changes during a sepsis-like state in cancer immunotherapy.
J Endotoxin Res. 2003;9(2):91–5.
25. Rai R, Nagral S, Nagral A. Surgery in a patient with liver disease. J Clin Exp
Hepatol. 2012;2(3):238–46.
26. Moller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol. 2010;53(1):179–90.
27. Birkmeyer JD, Finks JF, O’Reilly A, Oerline M, Carlin AM, Nunn AR, et al.
Surgical skill and complication rates after bariatric surgery. N Engl J Med.
2013;369(15):1434–42.
28. Arranz J, Soriano A, Garcia I, Garcia I, Concepcion MT, Navarro J, et al. Effect
of proinflammatory cytokines (IL-6, TNF-alpha, IL-1beta) on hemodynamic
performance during orthotopic liver transplantation. Transplant Proc.
2003;35(5):1884–7.
29. Krag A, Bendtsen F, Dahl EK, Kjaer A, Petersen CL, Moller S. Cardiac function
in patients with early cirrhosis during maximal beta-adrenergic drive: a
dobutamine stress study. PloS One. 2014;9(10):e109179.
30. Silvestre OM, Bacal F, de Souza RD, Andrade JL, Furtado M, Pugliese V, et al.
Impact of the severity of end-stage liver disease in cardiac structure and
function. Ann Hepatol. 2013;12(1):85–91.
31. Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts
development of hepatorenal syndrome and survival in patients with
cirrhosis and ascites. Gut. 2010;59(1):105–10.
32. Nazar A, Guevara M, Sitges M, Terra C, Sola E, Guigou C, et al. LEFT
ventricular function assessed by echocardiography in cirrhosis: relationship
to systemic hemodynamics and renal dysfunction. J Hepatol. 2013;58(1):51–7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zalunardo et al. BMC Anesthesiology  (2015) 15:107 Page 9 of 9
